MIRA Pharmaceuticals to Participate in BIO 2025 in Boston and Highlights Ongoing Progress Across Clinical Program
MIAMI, FL / ACCESS Newswire / May 28, 2025 / MIRA Pharmaceuticals, Inc. (Nasdaq:MIRA) ('MIRA' or the 'Company'), a clinical-stage pharmaceutical company developing novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders, today announced that it will participate in the BIO International Convention 2025, taking place in Boston, MA from June 16-19, 2025. The Company has a full schedule of BIO One-on-One Partnering™ meetings planned as it explores potential licensing, strategic partnerships, and M&A opportunities.
The Company's lead candidate, Ketamir-2, a next-generation oral ketamine analog, is currently undergoing a Phase 1 clinical trial. With the second dosing cohort completed, the Company is now preparing to initiate the third cohort. Building on this momentum, MIRA anticipates initiating a Phase IIa study in neuropathic pain before the end of the year, advancing the development of what the Company believes could be a safe, effective non-opioid alternative for chronic pain management.
In addition, MIRA is advancing a series of preclinical studies with Ketamir-2, including models evaluating its potential in PTSD, as well as a topical formulation aimed at treating localized inflammatory pain. The Company is also finalizing regulatory filings related to its acquisition of SKNY Pharmaceuticals, Inc. ('SKNY'), with submission to the U.S. Securities and Exchange Commission (SEC) expected in the coming weeks. SKNY-1, SKNY's primary pharmaceutical candidate, is being developed as an oral therapeutic targeting smoking cessation and obesity, with activity at CB1, CB2, and MAO-B receptors.
'Our pipeline is advancing on all fronts, and we are focused on turning this scientific momentum into long-term value for patients and shareholders,' said Erez Aminov, Chief Executive Officer of MIRA. 'As we move closer to initiating Phase IIa and completing the SKNY transaction, we're actively exploring strategic opportunities to accelerate growth, including licensing and partnerships-especially in areas like chronic pain where non-opioid alternatives like Ketamir-2 are urgently needed.'
Dr. Angel, Chief Scientific Advisor at MIRA, added:
'We believe Ketamir-2 is paving the way for a new class of non-opioid therapies. The science is compelling, and the progress we have made is truly exciting. I look forward to sharing the depth of our work and the promising data we've generated with potential partners and investors.'
Cautionary Note Regarding Forward-Looking Statements
This press release and the statements of MIRA's management related thereto contain 'forward-looking statements,' which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as 'aims,' 'anticipates,' 'believes,' 'could,' 'estimates,' 'expects,' 'forecasts,' 'goal,' 'intends,' 'may,' 'plans,' 'possible,' 'potential,' 'seeks,' 'will,' and variations of these words or similar expressions that are intended to identify forward-looking statements. Any statements in this press release that are not historical facts may be deemed forward-looking. Any forward-looking statements in this press release are based on MIRA's current expectations, estimates, and projections only as of the date of this release and are subject to a number of risks and uncertainties (many of which are beyond MIRA's control) that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including related to MIRA's potential merger with SKNY Pharmaceuticals, Inc. These and other risks concerning MIRA's programs and operations are described in additional detail in the Annual Report on Form 10-K for the year ended December 31, 2024, and other SEC filings, which are on file with the SEC at www.sec.gov and MIRA's website at https://www.mirapharmaceuticals.com/investors/sec-filings. MIRA explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
Contact Information
Helga Moya
[email protected]
(786) 432-9792
SOURCE: MIRA Pharmaceuticals
press release
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
US refiners may see Q2 profit recover on stronger diesel margins
By Nicole Jao NEW YORK (Reuters) -Investors are expecting top U.S. refiners to report higher second-quarter profits, bouncing back from losses during the first three months of the year as unseasonably strong diesel margins boost earnings. Fuelmakers have reaped unexpected profits from producing key products in recent months, a respite after earnings slipped from record levels in 2022, when a recovery in demand following the COVID-19 pandemic and Russia's invasion of Ukraine lifted prices. Some forecasting groups had anticipated weaker margins this year as demand was expected to slow. While analysts expect a recovery from the previous quarter, profits are likely to be weaker than a year ago. "Refiners are up 20% year-to-date, with surprising counter-seasonal diesel crack strength supporting the group," said TD Cowen analyst Jason Gabelman. Product margins could potentially hold at elevated levels until autumn maintenance, Gabelman said. Diesel cracks averaged $17 per barrel during the second quarter, in line with the first quarter, but ended the three-month period higher at $21 per barrel, TPH & Co analyst Matthew Blair said in a note. U.S. distillate inventories reached five-year lows in early May thanks to strong exports and improving demand, which supported margins, Blair said. U.S. refinery distillate yields have also been low, likely due to a lighter crude slate. Valero, the second-largest U.S. refiner by capacity, is set to kick off refiner earnings on Thursday, with analysts forecasting a profit of $1.75 per share, down from $2.71 per share profit a year ago, according to data from LSEG. Marathon Petroleum, the top U.S. refiner by volume, is expected to report a per-share profit of $3.28, compared with a $4.12 per share profit a year ago, LSEG estimated. Phillips 66 is expected to report a profit of $1.69 per share, versus $2.31 per share profit a year ago, according to LSEG estimates. Both Marathon and Phillips 66 reported losses in the first quarter.
Yahoo
14 minutes ago
- Yahoo
DR Horton (DHI) Jumps 17% After Earnings Beat
We recently published . D.R. Horton, Inc. (NYSE:DHI) is one of Tuesday's top performers. DR Horton grew its share prices by 16.98 percent on Tuesday to close at $153.5 apiece after beating its earnings guidance for the third quarter of fiscal year 2025. In its earnings release, D.R. Horton, Inc. (NYSE:DHI) said revenues during the period settled at $9.22 billion, lower than the $9.96 billion registered in the same period last year, but were well above analyst consensus. Meanwhile, attributable net income dropped by 24 percent to $1.02 billion from $1.35 billion year-on-year. Commenting on the company's performance, D.R. Horton, Inc. (NYSE:DHI) Executive Chairman David Auld said that new home demand continued to be impacted by ongoing affordability constraints and cautious consumer sentiment. A construction site of a multi-family residential complex, a modern urban skyline in the background. He said he expected sales incentives to remain elevated in the fourth quarter of the year. That said, D.R. Horton, Inc. (NYSE:DHI) lowered the high-end range of its full-year revenue guidance for the fourth quarter to $34.2 billion from $34.8 billion previously, with homes closed now expected to settle at only 85,000 versus the 87,000 prior. While we acknowledge the potential of DHI as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
14 minutes ago
- Yahoo
530,000-square-foot industrial complex coming to this Pierce County property
A developer of industrial sites has announced plans for recently acquired parcels near Frederickson Town Center. In May, The News Tribune reported the acquisition of nearly 41 acres in the Frederickson area by Dermody of Reno, Nevada. Dermody is involved in e-commerce, logistics and industrial real-estate acquisition, development and investment management, according to its website. In a release Wednesday, Dermody outlined plans for a multi-building industrial center, complete with a new name. 'The fully entitled site will become LogistiCenter at Frederickson, housing two buildings – Building A and B — as well as a trailer lot,' the release stated. 'Building A will be a 443,420-square-foot facility, and Building B is 91,728 SF. The trailer lot will be 3+ acres.' It added, 'Both buildings have broken ground, with delivery anticipated in the second quarter of 2026.' Dermody acquired the site in May for $45.5 million from an LLC affiliated with Pallis Properties of Mercer Island. Pallis also developed the Frederickson Town Center retail site south of the industrial property. Plans had envisioned what was then called the Canyon Point Industrial Center at the now-Dermody LogistiCenter site. The news comes in the same week that The News Tribune reported that FRED310, a planned six-building industrial/warehouse complex also in the Frederickson area, sold its Building D to international real-estate investment firm BentallGreenOak (BGO) for $176 million. Dermody's Northwest region spans five states. It has concentrated its work in the Seattle and Portland regions. 'The Tacoma-Fife submarket is one of the most sought-after submarkets in the region due to its proximity to skilled labor, a large consumer base and access to the Ports of Seattle and Tacoma,' said Ben Seeger, Northwest Region Partner at Dermody in the release. 'There is limited land available for development in this area and this was the best located developable land site of scale left in Frederickson, with great proximity to the major transportation networks in the region.' Leasing brokers for the Dermody project are CBRE's Andrew Hitchcock, executive vice president; Andrew Stark, executive vice president and Zac Snedeker, senior vice president. Previous reporting from The News Tribune contributed to this report.
